Most manufacturers know Inmar for pharmacy returns and consumer drug takeback programs. | Emily Welker explains how retail ...
The pharmaceutical patient journey has always been complex, but today's media environment presents more touchpoints than ever ...
Life sciences organizations have invested heavily in data and analytics, yet timely decision making remains a challenge. | ...
AI is transforming healthcare by making guidelines, clinical trial data and emerging research more accessible than ever. | AI delivers information. Peer validation delivers confidence. Learn how HCP ...
All told, GSK is plugging more than $800 million into an overhaul of its facilities in Upper Merion Township, where ...
Revolution Medicines’ stock slid 6.3% Thursday after newly released FDA review documents sparked investor unease around ...
After a year of rocky financials and trial readouts, Quince Therapeutics is charting a new path forward and relaunching with ...
With a Friday go-ahead from the FDA, another key piece of Teva’s innovation revamp strategy has fallen into place, further ...
Arcutis Biotherapeutics has lined up another celeb to tout the benefits of its topical skin medicine Zoryve, adding ...
Pfizer bagged a coveted first-line maintenance approval for Tukysa. In combination with HER2 antibody drugs, the treatment ...
Novartis bought an mRNA-coded autoimmune T-cell engager candidate for up to $7.8 billion, as Shionogi offered $2 billion to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results